February 2026 Promo Code — Up to 20% OFF EpiCypher

They launched the epigenetics business EpiCypher in 2012 in response to the rising need for high-quality reagents and tools to research chromatin regulation and support epigenetics-focused medication development. The manufacture and development of recombinant nucleosomes are led by EpiCypher on a global scale. They are constantly expanding the greatest collection of very pure customized recombinant "designer" nucleosomes (dNucsTM) in the world using their own patented techniques. The vast dNucTM diversity offered by Epicypher is a potent tool for unlocking the histone code and accelerating drug development. The many advantages of employing nucleosome substrates for epigenetics research are illustrated by Shah et al, Wang et al, and Weinberg et al. For a variety of applications, such as SNAP-ChIP® Spike-in Controls (for antibody profiling and quantitative ChIP), EpiDyne® substrates (for describing chromatin remodeling enzyme complexes and inhibitors), and dCypherTM assays, Epicypher makes use of dNucTM technology (for interrogation of epigenetic protein-histone PTM binding interactions).